Endocyte, Inc.: Series C $26M

Posted in I - Series C, Q - 4Q09, R - MID WEST, X - Oncology, X - Therapeutic Platform, XX - IN

Endocyte (West Lafayette, IN) a clinical-stage biopharmaceutical focused on folate-receptor targeted receptors in ovarian, NSCLC and breast cancers and renal cell carcinoma, closed a $26M Series B financing. Participants include Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co. and Triathlon Medical Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Oct

2009

PrimeraDx, Inc.: Series C $20M

Posted in I - Series C, Q - 3Q09, R - NORTH EAST, X - Antiinfective, X - Device (Diagnostic), XX - MA

PrimeraDx (Mansfield, MA) a development-stage molecular diagnostics company focused on automated multiplexed assays of infectious disease testing in immune compromised patients undergoing solid organ and bone marrow transplant, closed a $20M Series C financing. Participants include CHL Medical Partners, Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Co. and Invus.

to top of page...